BNB PLUS CORP.

BNB PLUS CORP. completed an unregistered sale of equity securities, raising $2.5 million. The company issued 2,380,953 shares of Series B-1 Preferred Stock and Common Warrants at $1.05 per share. Additionally, it entered into an Inducement Agreement for Series E Warrants totaling approximately $0.22 million, with an initial closing for other Inducement Agreements expected to bring in about $1.72 million by June 9, 2026. These issuances were made under exemptions from SEC registration requirements.

BNB Plus Corp. has secured initial commitments for $4.1 million in convertible preferred stock financing, aiming for total proceeds of $5.0 million. This financing will bolster the company's digital asset treasury and provide working capital for a comprehensive strategic review of its digital asset and biotechnology businesses, led by GlobalStake Infrastructure. Following the anticipated proceeds, the company expects to hold over $16.4 million in cash and digital assets, and its LineaRx subsidiary achieved profitability in Q2 FY2026.